CN113166236A - 限制穿过黏液的合成粘合剂 - Google Patents

限制穿过黏液的合成粘合剂 Download PDF

Info

Publication number
CN113166236A
CN113166236A CN201980076739.1A CN201980076739A CN113166236A CN 113166236 A CN113166236 A CN 113166236A CN 201980076739 A CN201980076739 A CN 201980076739A CN 113166236 A CN113166236 A CN 113166236A
Authority
CN
China
Prior art keywords
fab
igg
amino acid
seq
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980076739.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·莱
B·什雷斯塔
A·谢弗
T·雅各布斯
T·芒什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mukmann Co ltd
University of North Carolina at Chapel Hill
Original Assignee
Mukmann Co ltd
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mukmann Co ltd, University of North Carolina at Chapel Hill filed Critical Mukmann Co ltd
Priority to CN202410028119.3A priority Critical patent/CN117838855A/zh
Publication of CN113166236A publication Critical patent/CN113166236A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1235—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980076739.1A 2018-09-21 2019-09-23 限制穿过黏液的合成粘合剂 Pending CN113166236A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410028119.3A CN117838855A (zh) 2018-09-21 2019-09-23 限制穿过黏液的合成粘合剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734771P 2018-09-21 2018-09-21
US62/734,771 2018-09-21
PCT/US2019/052396 WO2020061560A1 (en) 2018-09-21 2019-09-23 Synthetic binding agents for limiting permeation through mucus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410028119.3A Division CN117838855A (zh) 2018-09-21 2019-09-23 限制穿过黏液的合成粘合剂

Publications (1)

Publication Number Publication Date
CN113166236A true CN113166236A (zh) 2021-07-23

Family

ID=69887960

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980076739.1A Pending CN113166236A (zh) 2018-09-21 2019-09-23 限制穿过黏液的合成粘合剂
CN202410028119.3A Pending CN117838855A (zh) 2018-09-21 2019-09-23 限制穿过黏液的合成粘合剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410028119.3A Pending CN117838855A (zh) 2018-09-21 2019-09-23 限制穿过黏液的合成粘合剂

Country Status (7)

Country Link
US (1) US20210347885A1 (https=)
EP (1) EP3853249A4 (https=)
JP (2) JP7842564B2 (https=)
CN (2) CN113166236A (https=)
AU (1) AU2019343952A1 (https=)
CA (1) CA3113059A1 (https=)
WO (1) WO2020061560A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023030311A1 (zh) * 2021-08-31 2023-03-09 上海医药集团股份有限公司 靶向Siglec15的抗原结合蛋白及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570763B2 (en) * 2020-05-28 2026-03-10 The Board Of Trustees Of The Leland Stanford Junior University Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces
GB202309981D0 (en) * 2023-06-30 2023-08-16 Kbio Holdings Ltd Antibody
GB202319645D0 (en) * 2023-12-20 2024-01-31 Kbio Holdings Ltd Hexameric protein
WO2026055315A1 (en) * 2024-09-05 2026-03-12 Stirx, Inc. Humanized monoclonal antibodies, methods of making and treatment of neisseria gonorrhea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822288A1 (en) * 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
US20160222130A1 (en) * 2014-07-15 2016-08-04 Astellas Pharma Inc. Novel anti-human tie-2 antibody
CN107903325A (zh) * 2011-05-16 2018-04-13 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5227160A (en) 1988-07-15 1993-07-13 The Biomembrane Institute Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6045786A (en) 1989-02-01 2000-04-04 Johns Hopkins University Topical application of antibodies for prophylaxis against sexually transmitted diseases and pregnancy
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7211255B2 (en) 1996-01-29 2007-05-01 United States Of America The U.S. Environmental Protection Agency Contraceptives based on SP22 and SP22 antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US7125550B2 (en) 2000-01-19 2006-10-24 University Of Virginia Patent Foundation Human sperm specific lysozyme-like proteins
EP1255831A2 (en) 2000-01-19 2002-11-13 The University Of Virginia Patent Foundation Sperm specific proteins
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
JP2004535794A (ja) 2001-05-03 2004-12-02 チルドレンズ・メディカル・センター・コーポレイション 精子特異的カチオンチャネルおよびその使用
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1448589A4 (en) 2001-10-22 2005-03-30 Childrens Medical Center THE SPERM SPECIFIC CATION CHANNEL CATSPER2 AND USES THEREOF
WO2004015067A2 (en) 2002-08-07 2004-02-19 Children's Medical Center Corporation Sperm-specific cation channel, catsper-3, and uses therefor
WO2004015066A2 (en) 2002-08-07 2004-02-19 Children's Medical Center Corporation Sperm-specific cation channel, catsper-4, and uses therefor
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
WO2006050166A2 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
US20090030187A1 (en) * 2005-03-14 2009-01-29 Tous Guillermo I Macromolecules comprising a thioether cross-link
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US20110008329A1 (en) 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
KR20110084196A (ko) 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
WO2014070786A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018064603A1 (en) * 2016-09-30 2018-04-05 The University Of North Carolina At Chapel Hill Compositions and methods for crosslinking fc receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822288A1 (en) * 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
CN107903325A (zh) * 2011-05-16 2018-04-13 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
US20160222130A1 (en) * 2014-07-15 2016-08-04 Astellas Pharma Inc. Novel anti-human tie-2 antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN KLEIN等: "The use of CrossMAb technology for the generation of bi- and multispecific antibodies", 《MABS》, vol. 8, no. 6, pages 1010 - 1020, XP055375293, DOI: 10.1080/19420862.2016.1197457 *
JAI MARATHE等: "Antibodies to CD52g, a Secreted Sperm coating Antigen, Agglutinate Seminal Leukocytes and Prevent their Infiltration into Vaginal Epithelium", 《AIDS RESEARCH AND HUMAN RETROVIRUSES》, vol. 30, no. 1, pages 246 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023030311A1 (zh) * 2021-08-31 2023-03-09 上海医药集团股份有限公司 靶向Siglec15的抗原结合蛋白及其用途

Also Published As

Publication number Publication date
CN117838855A (zh) 2024-04-09
JP7842564B2 (ja) 2026-04-08
EP3853249A4 (en) 2022-06-22
JP2025170257A (ja) 2025-11-18
CA3113059A1 (en) 2020-03-26
EP3853249A1 (en) 2021-07-28
WO2020061560A1 (en) 2020-03-26
JP2022502488A (ja) 2022-01-11
AU2019343952A1 (en) 2021-04-22
US20210347885A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
CN107922496B (zh) IL2Rβ/通用γ链抗体
CN113166236A (zh) 限制穿过黏液的合成粘合剂
CN107207604B (zh) 抗alk2抗体
CN111954680B (zh) IL2Rβ/共同γ链抗体
CN109641037B (zh) 抗psma抗体及其用途
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
CN110573528B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
CN110382542B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
CN113372434A (zh) 包含tnf家族配体三聚体的抗原结合分子
AU2016280190B9 (en) Cys80 conjugated immunoglobulins
CN115151570B (zh) 抗人cd19抗体
AU2017276336A1 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
TW202212354A (zh) 用於病毒治療劑中之多向生物運輸的材料及方法
CN111094340B (zh) 抗Abeta抗体、其抗原结合片段及应用
US20230399385A1 (en) Neutralizing antibodies against sars-cov-2
TWI915520B (zh) 含抗tslp抗體的藥物組合物
RU2820351C2 (ru) Триспецифические связывающие белки, связывающие cd38, cd28 и cd3, а также способы применения для лечения вирусной инфекции
US20240262892A1 (en) Neutralizing antibodies against sars-cov-2
HK40109194A (zh) 抗体
HK40019153A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40015870A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40019153B (en) Bispecific antigen binding molecule for a costimulatory tnf receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723